» Articles » PMID: 18381930

Endoglin (CD105): a Marker of Tumor Vasculature and Potential Target for Therapy

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2008 Apr 3
PMID 18381930
Citations 182
Authors
Affiliations
Soon will be listed here.
Abstract

Endoglin (CD105) is an accessory protein of the transforming growth factor-beta receptor system expressed on vascular endothelial cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases. Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.

Citing Articles

ENDOGLIN (CD105): A marker of tumour vasculature for assessment of malignant potential of oral submucous fibrosis.

Shetty S, Pereira T, Tamgadge S, Kale S, Kamat P, Kumar S J Oral Maxillofac Pathol. 2025; 28(4):589-595.

PMID: 39949694 PMC: 11819617. DOI: 10.4103/jomfp.jomfp_67_24.


Age-dependent loss of HAPLN1 erodes vascular integrity via indirect upregulation of endothelial ICAM1 in melanoma.

Marino-Bravante G, Carey A, Huser L, Dixit A, Wang V, Kaur A Nat Aging. 2024; 4(3):350-363.

PMID: 38472454 DOI: 10.1038/s43587-024-00581-8.


A single nuclear transcriptomic characterisation of mechanisms responsible for impaired angiogenesis and blood-brain barrier function in Alzheimer's disease.

Tsartsalis S, Sleven H, Fancy N, Wessely F, Smith A, Willumsen N Nat Commun. 2024; 15(1):2243.

PMID: 38472200 PMC: 10933340. DOI: 10.1038/s41467-024-46630-z.


KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.

Zhou S, Abdihamid O, Tan F, Zhou H, Liu H, Li Z Cell Commun Signal. 2024; 22(1):153.

PMID: 38414063 PMC: 10898159. DOI: 10.1186/s12964-023-01411-x.


Digoxin-Mediated Inhibition of Potential Hypoxia-Related Angiogenic Repair in Modulated Electro-Hyperthermia (mEHT)-Treated Murine Triple-Negative Breast Cancer Model.

Bokhari S, Aloss K, Leroy Viana P, Schvarcz C, Besztercei B, Giunashvili N ACS Pharmacol Transl Sci. 2024; 7(2):456-466.

PMID: 38357275 PMC: 10863435. DOI: 10.1021/acsptsci.3c00296.